{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypokalemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Transaminitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Grade 3 related gastrointestinal toxicity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Common dose limiting toxicities.","groups":[{"description":"Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.\n\nvorinostat: Given PO\n\nrituximab: Given IV\n\nifosfamide: Given IV\n\ncarboplatin: Given IV\n\netoposide: Given IV\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies\n\ngene expression analysis: Correlative studies","id":"OG000","title":"Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3-5 weeks post end of treatment","title":"Safety and Toxicity According to CTCAE v3.0","type":"PRIMARY","unitOfMeasure":"Participants"}